|
1
|
Roufosse F: Management of
hypereosinophilic syndromes. Immunol Allergy Clin N Am. 35:561–575.
2015. View Article : Google Scholar
|
|
2
|
Cools J, DeAngelo DJ, Gotlib J, Stover EH,
Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, et
al: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1
genes as a therapeutic target of imatinib in idiopathic
hypereosinophilic syndrome. N Engl J Med. 348:1201–1214. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Klion AD: How I treat hypereosinophilic
syndromes. Blood. 126:1069–1077. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hardy WR and Anderson RE: The
hypereosinophilic syndromes. Ann Intern Med. 68:1220–1229. 1968.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mankad R, Bonnichsen C and Mankad S:
Hypereosinophilic syndrome: Cardiac diagnosis and management.
Heart. 102:100–106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cogan E and Roufosse F: Clinical
management of the hypereosinophilic syndromes. Expert Rev Hematol.
5:275–289. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ronchi Junior I, Vasconcelos Krebs CN,
Pietrovicz J, Nocera VB, Pedri LE, Fouani MM, Lopes GL, Loidi de
Santana WM, Akiyoshi C and Henriques C: Síndrome hipereosinofílica
idiopática. Relato de caso e revisão de literatura. Rev Bras Clin
Med. 8:177–182. 2010.
|
|
8
|
Kalac M, Quintás-Cardama A, Vrhovac R,
Kantarjian H and Verstovsek S: A critical appraisal of conventional
and investigational drug therapy in patients with hypereosinophilic
syndrome and clonal eosinophilia. Cancer. 110:955–964. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brito-Babapulle F: The eosinophilias,
including the idiopathic hypereosinophilic syndrome. Br J Haematol.
121:203–223. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Benezet-Mazuecos J, Marcos-Alberca P,
Farré J, Orejas M, de la Fuente A and Prieto E: Images in
cardiovascular medicine. Early differential resolution of right and
left ventricular obliteration in Löffler endocarditis after
chemotherapy and anticoagulation. Circulation. 114:e635–e637. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Curtis C and Ogbogu P: Hypereosinophilic
syndrome. Clinic Rev Allerg Immunol. 50:240–251. 2016. View Article : Google Scholar
|
|
12
|
Crane MM, Chang CM, Kobayashi MG and
Weller PF: Incidence of myeloproliferative hypereosinophilic
syndrome in the United States and an estimate of all
hypereosinophilic syndrome incidence. J Allergy Clin Immunol.
126:179–181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bain BJ, Gilliland DG, Horny HP, et al:
Myeloid and lymphoid neoplasms with eosinophilia and abnormalities
of PDGFRA, PDGFRB or FGFR1. World Health Organization
classification of tumors of hematopoietic and lymphoid tissues:
68–73. Lyon. France; IARC Press; 2008
|
|
14
|
Ogbogu PU, Bochner BS, Butterfield JH,
Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F,
Ring J, et al: Hypereosinophilic syndrome: A multicenter,
retrospective analysis of clinical characteristics and response to
therapy. J Allergy Clin Immunol. 124:1319–1325.e3. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gotlib J: World Health
Organization-defined eosinophilic disorders: 2015 update on
diagnosis, risk stratification, and management. Am J Hematol.
90:1078–1089. 2015. View Article : Google Scholar
|
|
16
|
Baccarani M, Cilloni D, Rondoni M,
Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni
N, Gottardi E, et al: The efficacy of imatinib mesylate in patients
with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results
of a multicenter prospective study. Haematologica. 92:1173–1179.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Metzgeroth G, Walz C, Erben P, Popp H,
Schmitt-Graeff A, Haferlach C, Fabarius A, Schnittger S, Grimwade
D, Cross NC, et al: Safety and efficacy of imatinib in chronic
eosinophilic leukaemia and hypereosinophilic syndrome: A phase-II
study. Br J Haematol. 143:707–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Khoury P, Desmond R, Pabon A,
Holland-Thomas N, Ware JM, Arthur DC, Kurlander R, Fay MP, Maric I
and Klion AD: Clinical features predict responsiveness to imatinib
in platelet-derived growth factor receptor-alpha-negative
hypereosinophilic syndrome. Allergy. 71:803–810. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weller PF and Bubley GJ: The idiopathic
hypereosinophilic syndrome. Blood. 83:2759–2779. 1994.PubMed/NCBI
|
|
20
|
Madhwal S, Goldberg J, Barcena J, Guha A,
Gogate P, Cmolik B and Elgudin Y: Unusual cause of acute mitral
regurgitation: Idiopathic hypereosinophilic syndrome. Ann Thorac
Surg. 93:974–977. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim NK, Kim CY, Kim JH, Jang SY, Bae MH,
Lee JH, Yang DH, Park HS, Cho Y and Chae SC: A hypereosinophilic
syndrome with cardiac involvement from thrombotic stage to fibrotic
stage. J Cardiovasc Ultrasound. 23:100–102. 2015. View Article : Google Scholar : PubMed/NCBI
|
